This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (58)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Pathology & Laboratory Medicine  • Drug Therapy  • Adverse Effects  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Franco Lori, MD; Julianna Lisziewicz, PhD

JAMA. 2001;286:2981-2987.

Antiretroviral drugs constitute a milestone in the treatment of human immunodeficiency virus (HIV) infection; however, emerging problems limit their long-term use, and an increasing number of patients interrupt the prescribed continuous drug therapy for short or long periods. Some patients appear to benefit from structured treatment interruptions (STI), involving monitored repetition of on-and-off cycles of drugs; however, it is unclear whether patients and/or physicians should consider STI as a treatment option.

This review is intended to provide a comprehensive update on the use of STI in clinical settings, and to carefully evaluate the advantages and potential risks for patients infected with HIV. We used a MEDLINE search to find all English-language articles published January 1999 to August 2001 regarding patients treated with highly active antiretroviral therapy for whom treatment interruption was investigated. Priority was assigned to peer-reviewed sources, when available. Otherwise, abstracts from authoritative international conferences were selected through the AIDSLINE database.

Results from various studies with respect to type of drug treatment, baseline patient status, number of treatment interruptions, duration of treatment and interruption, changes in viral load, and immune system parameters were analyzed. Patients could be categorized into 3 distinct clinical scenarios: acute infection, chronic drug-suppressed infection and virological drug failure. The STI approach may offer more benefit during acute infection when the patient's immune system remains nearly intact. It is yet to be determined whether STI will facilitate the long-term management of chronic infection by decreasing drug-associated toxicity and improving quality of life without jeopardizing the efficacy of the treatment. Results from randomized controlled trials and more definitive means of gauging the status of the patient's immune system must be available before this treatment method is extended beyond the research setting. Ultimately, a safer approach using therapeutic immunization or vaccination would be preferable for stimulating vigorous T-cell–mediated immune responses and control of HIV during treatment interruption.

Author Affiliations: Research Institute for Genetic and Human Therapy (RIGHT), Washington, DC, and Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

December 19, 2001
JAMA. 2001;286(23):3023-3024.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection
Mehandru et al.
J. Virol. 2007;81:11016-11031.
ABSTRACT | FULL TEXT  

CD4+ Count-Guided Interruption of Antiretroviral Treatment
The Strategies for Management of Antiretroviral Th
NEJM 2006;355:2283-2296.
ABSTRACT | FULL TEXT  

Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies
Aquaro et al.
J. Leukoc. Biol. 2006;80:1103-1110.
ABSTRACT | FULL TEXT  

Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.
Van Rompay et al.
J. Virol. 2006;80:6399-6410.
ABSTRACT | FULL TEXT  

Vaccination of Macaques with Long-Standing SIVmac251 Infection Lowers the Viral Set Point After Cessation of Antiretroviral Therapy
Tryniszewska et al.
J. Immunol. 2002;169:5347-5357.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Do Not Predict Viral Growth and Clearance Rates during Structured Intermittent Antiretroviral Therapy
Oxenius et al.
J. Virol. 2002;76:10169-10176.
ABSTRACT | FULL TEXT  

Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel
Yeni et al.
JAMA 2002;288:222-235.
ABSTRACT | FULL TEXT  

Can Structured Treatment Interruptions (STIs) Be Used as a Strategy to Decrease Total Drug Requirements and Toxicity in HIV Infection?
Walmsley and Loutfy
J Int Assoc Physicians AIDS Care (Chic Ill) 2002;1:95-103.
ABSTRACT